ID   KPCB_RAT                Reviewed;         671 AA.
AC   P68403; P04410; P04411;
DT   13-AUG-1987, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   02-OCT-2024, entry version 179.
DE   RecName: Full=Protein kinase C beta type;
DE            Short=PKC-B;
DE            Short=PKC-beta;
DE            EC=2.7.11.13 {ECO:0000250|UniProtKB:P05771};
GN   Name=Prkcb; Synonyms=Pkcb, Prkcb1;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS BETA-I AND BETA-II).
RX   PubMed=3755379; DOI=10.1016/0092-8674(86)90874-3;
RA   Knopf J.L., Lee M.-H., Sultzman L.A., Kriz R.W., Loomis C.R., Hewick R.M.,
RA   Bell R.M.;
RT   "Cloning and expression of multiple protein kinase C cDNAs.";
RL   Cell 46:491-502(1986).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORMS BETA-I AND BETA-II).
RC   TISSUE=Brain;
RX   PubMed=2428667; DOI=10.1016/0014-5793(86)81010-9;
RA   Ono Y., Kurokawa T., Fujii T., Kawahara K., Igarashi K., Kikkawa U.,
RA   Ogita K., Nishizuka Y.;
RT   "Two types of complementary DNAs of rat brain protein kinase C.
RT   Heterogeneity determined by alternative splicing.";
RL   FEBS Lett. 206:347-352(1986).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM BETA-I).
RC   TISSUE=Fibroblast;
RX   PubMed=3345563; DOI=10.1016/s0092-8674(88)80027-8;
RA   Housey G.M., Johnson M.D., Hsiao W.L.W., O'Brian C.A., Murphy J.P.,
RA   Kirschmeier P., Weinstein I.B.;
RT   "Overproduction of protein kinase C causes disordered growth control in rat
RT   fibroblasts.";
RL   Cell 52:343-354(1988).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 448-671 (ISOFORM BETA-I).
RX   PubMed=3755404; DOI=10.1016/0014-5793(86)80724-4;
RA   Ono Y., Kurokawa T., Kawahara K., Nishimura O., Marumoto R., Igarashi K.,
RA   Sugino Y., Kikkawa U., Ogita K., Nishizuka Y.;
RT   "Cloning of rat brain protein kinase C complementary DNA.";
RL   FEBS Lett. 203:111-115(1986).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 448-671 (ISOFORM BETA-I).
RX   PubMed=3469647; DOI=10.1073/pnas.84.4.1065;
RA   Housey G.M., O'Brian C.A., Johnson M.D., Kirschmeier P., Weinstein I.B.;
RT   "Isolation of cDNA clones encoding protein kinase C: evidence for a protein
RT   kinase C-related gene family.";
RL   Proc. Natl. Acad. Sci. U.S.A. 84:1065-1069(1987).
RN   [6]
RP   PROTEIN SEQUENCE OF 500-520 AND 636-663 (ISOFORM BETA-II), AND
RP   PHOSPHORYLATION AT THR-500; THR-642 AND SER-661.
RX   PubMed=8749392; DOI=10.1016/s0960-9822(95)00277-6;
RA   Keranen L.M., Dutil E.M., Newton A.C.;
RT   "Protein kinase C is regulated in vivo by three functionally distinct
RT   phosphorylations.";
RL   Curr. Biol. 5:1394-1403(1995).
RN   [7]
RP   PHOSPHORYLATION AT SER-16; THR-17; THR-314; THR-324; THR-635 AND THR-642,
RP   AND MUTAGENESIS OF 16-SER-THR-17; THR-314; THR-324; THR-635 AND THR-642.
RX   PubMed=8327493; DOI=10.1073/pnas.90.13.6130;
RA   Zhang J., Wang L., Petrin J., Bishop W.R., Bond R.W.;
RT   "Characterization of site-specific mutants altered at protein kinase C beta
RT   1 isozyme autophosphorylation sites.";
RL   Proc. Natl. Acad. Sci. U.S.A. 90:6130-6134(1993).
RN   [8]
RP   PHOSPHORYLATION AT THR-642 (ISOFORM BETA-I), AND MUTAGENESIS OF THR-635 AND
RP   THR-642.
RX   PubMed=8034726; DOI=10.1016/s0021-9258(17)32208-1;
RA   Zhang J., Wang L., Schwartz J., Bond R.W., Bishop W.R.;
RT   "Phosphorylation of Thr642 is an early event in the processing of newly
RT   synthesized protein kinase C beta 1 and is essential for its activation.";
RL   J. Biol. Chem. 269:19578-19584(1994).
RN   [9]
RP   PHOSPHORYLATION AT THR-500, AND MUTAGENESIS OF THR-500.
RX   PubMed=7961692; DOI=10.1016/s0021-9258(18)47044-5;
RA   Orr J.W., Newton A.C.;
RT   "Requirement for negative charge on 'activation loop' of protein kinase
RT   C.";
RL   J. Biol. Chem. 269:27715-27718(1994).
RN   [10]
RP   FUNCTION IN INSULIN SIGNALING.
RX   PubMed=10938109; DOI=10.1128/mcb.20.17.6323-6333.2000;
RA   Formisano P., Oriente F., Fiory F., Caruso M., Miele C., Maitan M.A.,
RA   Andreozzi F., Vigliotta G., Condorelli G., Beguinot F.;
RT   "Insulin-activated protein kinase Cbeta bypasses Ras and stimulates
RT   mitogen-activated protein kinase activity and cell proliferation in muscle
RT   cells.";
RL   Mol. Cell. Biol. 20:6323-6333(2000).
RN   [11]
RP   FUNCTION IN INSULIN SIGNALING.
RX   PubMed=11714718; DOI=10.1074/jbc.m109647200;
RA   Kaneto H., Suzuma K., Sharma A., Bonner-Weir S., King G.L., Weir G.C.;
RT   "Involvement of protein kinase C beta 2 in c-myc induction by high glucose
RT   in pancreatic beta-cells.";
RL   J. Biol. Chem. 277:3680-3685(2002).
RN   [12]
RP   FUNCTION.
RX   PubMed=19176525; DOI=10.1074/jbc.m808719200;
RA   Yamasaki T., Takahashi A., Pan J., Yamaguchi N., Yokoyama K.K.;
RT   "Phosphorylation of activation transcription factor-2 at serine 121 by
RT   protein kinase c controls c-Jun-mediated activation of transcription.";
RL   J. Biol. Chem. 284:8567-8581(2009).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-11 AND THR-642,
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-641; SER-654; SER-660 AND
RP   SER-664 (ISOFORM BETA-II), AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE
RP   SCALE ANALYSIS].
RX   PubMed=22673903; DOI=10.1038/ncomms1871;
RA   Lundby A., Secher A., Lage K., Nordsborg N.B., Dmytriyev A., Lundby C.,
RA   Olsen J.V.;
RT   "Quantitative maps of protein phosphorylation sites across 14 different rat
RT   organs and tissues.";
RL   Nat. Commun. 3:876-876(2012).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 157-288 IN COMPLEX WITH CALCIUM
RP   IONS, AND COFACTOR.
RX   PubMed=9817842; DOI=10.1016/s0969-2126(98)00139-7;
RA   Sutton R.B., Sprang S.R.;
RT   "Structure of the protein kinase Cbeta phospholipid-binding C2 domain
RT   complexed with Ca2+.";
RL   Structure 6:1395-1405(1998).
RN   [15]
RP   X-RAY CRYSTALLOGRAPHY (4.00 ANGSTROMS) OF 1-661 IN COMPLEX WITH CALCIUM
RP   IONS, COFACTOR, AND PHOSPHORYLATION AT THR-500; THR-642 AND SER-661.
RX   PubMed=21215369; DOI=10.1016/j.cell.2010.12.013;
RA   Leonard T.A., Rozycki B., Saidi L.F., Hummer G., Hurley J.H.;
RT   "Crystal structure and allosteric activation of protein kinase C betaII.";
RL   Cell 144:55-66(2011).
CC   -!- FUNCTION: Calcium-activated, phospholipid- and diacylglycerol (DAG)-
CC       dependent serine/threonine-protein kinase involved in various cellular
CC       processes such as regulation of the B-cell receptor (BCR) signalosome,
CC       oxidative stress-induced apoptosis, androgen receptor-dependent
CC       transcription regulation, insulin signaling and endothelial cells
CC       proliferation. Plays a key role in B-cell activation by regulating BCR-
CC       induced NF-kappa-B activation. Mediates the activation of the canonical
CC       NF-kappa-B pathway (NFKB1) by direct phosphorylation of CARD11/CARMA1
CC       at 'Ser-559', 'Ser-644' and 'Ser-652'. Phosphorylation induces
CC       CARD11/CARMA1 association with lipid rafts and recruitment of the
CC       BCL10-MALT1 complex as well as MAP3K7/TAK1, which then activates IKK
CC       complex, resulting in nuclear translocation and activation of NFKB1.
CC       Plays a direct role in the negative feedback regulation of the BCR
CC       signaling, by down-modulating BTK function via direct phosphorylation
CC       of BTK at 'Ser-180', which results in the alteration of BTK plasma
CC       membrane localization and in turn inhibition of BTK activity. Involved
CC       in apoptosis following oxidative damage: in case of oxidative
CC       conditions, specifically phosphorylates 'Ser-36' of isoform p66Shc of
CC       SHC1, leading to mitochondrial accumulation of p66Shc, where p66Shc
CC       acts as a reactive oxygen species producer. Acts as a coactivator of
CC       androgen receptor (ANDR)-dependent transcription, by being recruited to
CC       ANDR target genes and specifically mediating phosphorylation of 'Thr-6'
CC       of histone H3 (H3T6ph), a specific tag for epigenetic transcriptional
CC       activation that prevents demethylation of histone H3 'Lys-4' (H3K4me)
CC       by LSD1/KDM1A. In insulin signaling, may function downstream of IRS1 in
CC       muscle cells and mediate insulin-dependent DNA synthesis through the
CC       RAF1-MAPK/ERK signaling cascade. Participates in the regulation of
CC       glucose transport in adipocytes by negatively modulating the insulin-
CC       stimulated translocation of the glucose transporter SLC2A4/GLUT4.
CC       Phosphorylates SLC2A1/GLUT1, promoting glucose uptake by SLC2A1/GLUT1.
CC       Under high glucose in pancreatic beta-cells, is probably involved in
CC       the inhibition of the insulin gene transcription, via regulation of MYC
CC       expression. In endothelial cells, activation of PRKCB induces increased
CC       phosphorylation of RB1, increased VEGFA-induced cell proliferation, and
CC       inhibits PI3K/AKT-dependent nitric oxide synthase (NOS3/eNOS)
CC       regulation by insulin, which causes endothelial dysfunction. Also
CC       involved in triglyceride homeostasis (By similarity). Phosphorylates
CC       ATF2 which promotes cooperation between ATF2 and JUN, activating
CC       transcription. Phosphorylates KLHL3 in response to angiotensin II
CC       signaling, decreasing the interaction between KLHL3 and WNK4 (By
CC       similarity). Phosphorylates and activates LRRK1, which phosphorylates
CC       RAB proteins involved in intracellular trafficking (By similarity).
CC       {ECO:0000250|UniProtKB:P05771, ECO:0000250|UniProtKB:P68404,
CC       ECO:0000269|PubMed:10938109, ECO:0000269|PubMed:11714718,
CC       ECO:0000269|PubMed:19176525}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.13;
CC         Evidence={ECO:0000250|UniProtKB:P05771};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.13; Evidence={ECO:0000250|UniProtKB:P05771};
CC   -!- COFACTOR:
CC       Name=Ca(2+); Xref=ChEBI:CHEBI:29108;
CC         Evidence={ECO:0000255|PROSITE-ProRule:PRU00041,
CC         ECO:0000269|PubMed:21215369, ECO:0000269|PubMed:9817842};
CC       Note=Binds 3 Ca(2+) ions per subunit. The ions are bound to the C2
CC       domain. {ECO:0000269|PubMed:21215369, ECO:0000269|PubMed:9817842};
CC   -!- ACTIVITY REGULATION: Classical (or conventional) PKCs (PRKCA, PRKCB and
CC       PRKCG) are activated by calcium and diacylglycerol (DAG) in the
CC       presence of phosphatidylserine. Three specific sites; Thr-500
CC       (activation loop of the kinase domain), Thr-642 (turn motif) and Ser-
CC       661 (hydrophobic region), need to be phosphorylated for its full
CC       activation. Specifically inhibited by enzastaurin (LY317615) (By
CC       similarity). {ECO:0000250}.
CC   -!- SUBUNIT: Interacts with PDK1. Interacts in vitro with PRKCBP1.
CC       Interacts with PHLPP1 and PHLPP2; both proteins mediate its
CC       dephosphorylation. Interacts with KDM1A/LSD1, PKN1 and ANDR (By
CC       similarity). {ECO:0000250}.
CC   -!- INTERACTION:
CC       P68403; P18052: Ptpra; Xeno; NbExp=3; IntAct=EBI-397072, EBI-6597520;
CC       P68403-1; Q62920: Pdlim5; NbExp=5; IntAct=EBI-12559950, EBI-918433;
CC       P68403-2; Q8WV44-2: TRIM41; Xeno; NbExp=3; IntAct=EBI-397092, EBI-726015;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus {ECO:0000250}. Membrane;
CC       Peripheral membrane protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=Beta-I;
CC         IsoId=P68403-1, P04410-1;
CC         Sequence=Displayed;
CC       Name=Beta-II;
CC         IsoId=P68403-2, P04410-2;
CC         Sequence=VSP_004739;
CC   -!- PTM: Phosphorylation on Thr-500 of isoform beta-I, within the
CC       activation loop, renders it competent to autophosphorylate. Subsequent
CC       autophosphorylation of Thr-642 maintains catalytic competence, and
CC       autophosphorylation on Ser-661 appears to release the kinase into the
CC       cytosol. Similarly, isoform beta-II is autophosphorylated on 'Thr-641'
CC       and 'Ser-660', subsequent to phosphorylation on Thr-500.
CC       Autophosphorylated on other sites i.e. in the N-terminal and hinge
CC       regions have no effect on enzyme activity. Phosphorylation at Tyr-662
CC       by SYK induces binding with GRB2 and contributes to the activation of
CC       MAPK/ERK signaling cascade. {ECO:0000269|PubMed:21215369,
CC       ECO:0000269|PubMed:7961692, ECO:0000269|PubMed:8327493,
CC       ECO:0000269|PubMed:8749392}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr
CC       protein kinase family. PKC subfamily. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M13706; AAA41875.1; -; mRNA.
DR   EMBL; K03485; AAA41864.1; -; mRNA.
DR   EMBL; K03486; AAA41865.1; -; mRNA.
DR   EMBL; X04439; CAA28035.1; -; Genomic_DNA.
DR   EMBL; X04440; CAA28036.1; -; mRNA.
DR   EMBL; M19007; AAA41868.1; -; mRNA.
DR   EMBL; X04139; CAA27756.1; -; mRNA.
DR   EMBL; M15522; AAA41876.1; -; mRNA.
DR   PIR; A00622; KIRTC1.
DR   RefSeq; NP_001165776.1; NM_001172305.1.
DR   PDB; 1A25; X-ray; 2.70 A; A/B=154-289.
DR   PDB; 3PFQ; X-ray; 4.00 A; A=1-661.
DR   PDBsum; 1A25; -.
DR   PDBsum; 3PFQ; -.
DR   AlphaFoldDB; P68403; -.
DR   SMR; P68403; -.
DR   BioGRID; 247103; 17.
DR   IntAct; P68403; 7.
DR   MINT; P68403; -.
DR   STRING; 10116.ENSRNOP00000016417; -.
DR   BindingDB; P68403; -.
DR   ChEMBL; CHEMBL3020; -.
DR   DrugCentral; P68403; -.
DR   GlyGen; P68403; 4 sites, 1 O-linked glycan (4 sites).
DR   iPTMnet; P68403; -.
DR   PhosphoSitePlus; P68403; -.
DR   jPOST; P68403; -.
DR   PaxDb; 10116-ENSRNOP00000016417; -.
DR   Ensembl; ENSRNOT00000016418.7; ENSRNOP00000016417.5; ENSRNOG00000012061.9. [P68403-1]
DR   Ensembl; ENSRNOT00000078705.2; ENSRNOP00000073511.2; ENSRNOG00000012061.9. [P68403-2]
DR   Ensembl; ENSRNOT00055013848; ENSRNOP00055011102; ENSRNOG00055008014. [P68403-1]
DR   Ensembl; ENSRNOT00060053332; ENSRNOP00060044337; ENSRNOG00060030161. [P68403-1]
DR   Ensembl; ENSRNOT00065021344; ENSRNOP00065016504; ENSRNOG00065013001. [P68403-1]
DR   GeneID; 25023; -.
DR   KEGG; rno:25023; -.
DR   UCSC; RGD:3396; rat.
DR   AGR; RGD:3396; -.
DR   CTD; 5579; -.
DR   RGD; 3396; Prkcb.
DR   eggNOG; KOG0696; Eukaryota.
DR   GeneTree; ENSGT00940000155217; -.
DR   InParanoid; P68403; -.
DR   OMA; CKINVPN; -.
DR   OrthoDB; 841660at2759; -.
DR   PhylomeDB; P68403; -.
DR   BRENDA; 2.7.1.107; 5301.
DR   Reactome; R-RNO-114516; Disinhibition of SNARE formation.
DR   Reactome; R-RNO-1169091; Activation of NF-kappaB in B cells.
DR   Reactome; R-RNO-416993; Trafficking of GluR2-containing AMPA receptors.
DR   Reactome; R-RNO-4419969; Depolymerization of the Nuclear Lamina.
DR   Reactome; R-RNO-5099900; WNT5A-dependent internalization of FZD4.
DR   Reactome; R-RNO-5218921; VEGFR2 mediated cell proliferation.
DR   Reactome; R-RNO-5668599; RHO GTPases Activate NADPH Oxidases.
DR   Reactome; R-RNO-76005; Response to elevated platelet cytosolic Ca2+.
DR   EvolutionaryTrace; P68403; -.
DR   PRO; PR:P68403; -.
DR   Proteomes; UP000002494; Chromosome 1.
DR   GO; GO:0031526; C:brush border membrane; IDA:RGD.
DR   GO; GO:0044305; C:calyx of Held; ISO:RGD.
DR   GO; GO:0005813; C:centrosome; IDA:RGD.
DR   GO; GO:0005737; C:cytoplasm; ISO:RGD.
DR   GO; GO:0005654; C:nucleoplasm; IEA:Ensembl.
DR   GO; GO:0005634; C:nucleus; ISS:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; ISO:RGD.
DR   GO; GO:0099523; C:presynaptic cytosol; ISO:RGD.
DR   GO; GO:0008091; C:spectrin; ISO:RGD.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005246; F:calcium channel regulator activity; ISO:RGD.
DR   GO; GO:0003682; F:chromatin binding; ISS:UniProtKB.
DR   GO; GO:0004697; F:diacylglycerol-dependent serine/threonine kinase activity; IDA:RGD.
DR   GO; GO:0042393; F:histone binding; ISS:UniProtKB.
DR   GO; GO:0035403; F:histone H3T6 kinase activity; ISS:UniProtKB.
DR   GO; GO:0050681; F:nuclear androgen receptor binding; ISS:UniProtKB.
DR   GO; GO:0030374; F:nuclear receptor coactivator activity; ISS:UniProtKB.
DR   GO; GO:0005080; F:protein kinase C binding; ISO:RGD.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; ISO:RGD.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0002250; P:adaptive immune response; IEA:UniProtKB-KW.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0042113; P:B cell activation; ISS:UniProtKB.
DR   GO; GO:0050853; P:B cell receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0006816; P:calcium ion transport; ISO:RGD.
DR   GO; GO:0071322; P:cellular response to carbohydrate stimulus; ISO:RGD.
DR   GO; GO:0018894; P:dibenzo-p-dioxin metabolic process; IEP:RGD.
DR   GO; GO:0006874; P:intracellular calcium ion homeostasis; ISO:RGD.
DR   GO; GO:0035556; P:intracellular signal transduction; IBA:GO_Central.
DR   GO; GO:0010829; P:negative regulation of glucose transmembrane transport; ISS:UniProtKB.
DR   GO; GO:0046627; P:negative regulation of insulin receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0007207; P:phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathway; ISO:RGD.
DR   GO; GO:0045766; P:positive regulation of angiogenesis; ISS:UniProtKB.
DR   GO; GO:0050861; P:positive regulation of B cell receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0043123; P:positive regulation of canonical NF-kappaB signal transduction; ISS:UniProtKB.
DR   GO; GO:0032024; P:positive regulation of insulin secretion; ISO:RGD.
DR   GO; GO:0042488; P:positive regulation of odontogenesis of dentin-containing tooth; IEP:RGD.
DR   GO; GO:0030949; P:positive regulation of vascular endothelial growth factor receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0043687; P:post-translational protein modification; ISS:UniProtKB.
DR   GO; GO:0099171; P:presynaptic modulation of chemical synaptic transmission; ISO:RGD.
DR   GO; GO:0014059; P:regulation of dopamine secretion; IMP:RGD.
DR   GO; GO:0010827; P:regulation of glucose transmembrane transport; ISS:UniProtKB.
DR   GO; GO:0040008; P:regulation of growth; IMP:RGD.
DR   GO; GO:2000300; P:regulation of synaptic vesicle exocytosis; ISO:RGD.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; ISS:UniProtKB.
DR   GO; GO:0045471; P:response to ethanol; IEP:RGD.
DR   GO; GO:0009749; P:response to glucose; IEP:RGD.
DR   GO; GO:0033280; P:response to vitamin D; IEP:RGD.
DR   GO; GO:0009410; P:response to xenobiotic stimulus; IMP:RGD.
DR   CDD; cd20833; C1_cPKC_rpt1; 1.
DR   CDD; cd20836; C1_cPKC_rpt2; 1.
DR   CDD; cd04026; C2_PKC_alpha_gamma; 1.
DR   CDD; cd05616; STKc_cPKC_beta; 1.
DR   Gene3D; 3.30.60.20; -; 2.
DR   Gene3D; 2.60.40.150; C2 domain; 1.
DR   Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1.
DR   InterPro; IPR000961; AGC-kinase_C.
DR   InterPro; IPR046349; C1-like_sf.
DR   InterPro; IPR000008; C2_dom.
DR   InterPro; IPR035892; C2_domain_sf.
DR   InterPro; IPR034664; cPKC-beta.
DR   InterPro; IPR020454; DAG/PE-bd.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR002219; PE/DAG-bd.
DR   InterPro; IPR017892; Pkinase_C.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR014375; Protein_kinase_C_a/b/g.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   InterPro; IPR050236; Ser_Thr_kinase_AGC.
DR   PANTHER; PTHR24356:SF158; PROTEIN KINASE C BETA TYPE; 1.
DR   PANTHER; PTHR24356; SERINE/THREONINE-PROTEIN KINASE; 1.
DR   Pfam; PF00130; C1_1; 2.
DR   Pfam; PF00168; C2; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   Pfam; PF00433; Pkinase_C; 1.
DR   PIRSF; PIRSF000550; PKC_alpha; 1.
DR   PRINTS; PR00360; C2DOMAIN.
DR   PRINTS; PR00008; DAGPEDOMAIN.
DR   SMART; SM00109; C1; 2.
DR   SMART; SM00239; C2; 1.
DR   SMART; SM00133; S_TK_X; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF49562; C2 domain (Calcium/lipid-binding domain, CaLB); 1.
DR   SUPFAM; SSF57889; Cysteine-rich domain; 2.
DR   SUPFAM; SSF56112; Protein kinase-like (PK-like); 1.
DR   PROSITE; PS51285; AGC_KINASE_CTER; 1.
DR   PROSITE; PS50004; C2; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
DR   PROSITE; PS00479; ZF_DAG_PE_1; 2.
DR   PROSITE; PS50081; ZF_DAG_PE_2; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Adaptive immunity; Alternative splicing;
KW   Apoptosis; ATP-binding; Calcium; Chromatin regulator; Cytoplasm;
KW   Direct protein sequencing; Immunity; Kinase; Membrane; Metal-binding;
KW   Nucleotide-binding; Nucleus; Phosphoprotein; Reference proteome; Repeat;
KW   Serine/threonine-protein kinase; Transcription; Transcription regulation;
KW   Transferase; Zinc; Zinc-finger.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0000250|UniProtKB:P05771"
FT   CHAIN           2..671
FT                   /note="Protein kinase C beta type"
FT                   /id="PRO_0000055687"
FT   DOMAIN          158..275
FT                   /note="C2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00041"
FT   DOMAIN          342..600
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   DOMAIN          601..671
FT                   /note="AGC-kinase C-terminal"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00618"
FT   ZN_FING         36..86
FT                   /note="Phorbol-ester/DAG-type 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00226"
FT   ZN_FING         101..151
FT                   /note="Phorbol-ester/DAG-type 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00226"
FT   REGION          614..635
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        614..633
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        466
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10027"
FT   BINDING         186
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000269|PubMed:21215369,
FT                   ECO:0000269|PubMed:9817842"
FT   BINDING         187
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000269|PubMed:21215369,
FT                   ECO:0000269|PubMed:9817842"
FT   BINDING         187
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000269|PubMed:21215369,
FT                   ECO:0000269|PubMed:9817842"
FT   BINDING         193
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000269|PubMed:21215369,
FT                   ECO:0000269|PubMed:9817842"
FT   BINDING         246
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000269|PubMed:21215369,
FT                   ECO:0000269|PubMed:9817842"
FT   BINDING         246
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000269|PubMed:21215369,
FT                   ECO:0000269|PubMed:9817842"
FT   BINDING         247
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000269|PubMed:21215369,
FT                   ECO:0000269|PubMed:9817842"
FT   BINDING         248
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000269|PubMed:21215369,
FT                   ECO:0000269|PubMed:9817842"
FT   BINDING         248
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000269|PubMed:21215369,
FT                   ECO:0000269|PubMed:9817842"
FT   BINDING         248
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="3"
FT                   /evidence="ECO:0000269|PubMed:21215369,
FT                   ECO:0000269|PubMed:9817842"
FT   BINDING         251
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="3"
FT                   /evidence="ECO:0000269|PubMed:21215369,
FT                   ECO:0000269|PubMed:9817842"
FT   BINDING         252
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="3"
FT                   /evidence="ECO:0000269|PubMed:21215369,
FT                   ECO:0000269|PubMed:9817842"
FT   BINDING         254
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000269|PubMed:21215369,
FT                   ECO:0000269|PubMed:9817842"
FT   BINDING         254
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="3"
FT                   /evidence="ECO:0000269|PubMed:21215369,
FT                   ECO:0000269|PubMed:9817842"
FT   BINDING         348..356
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         371
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         2
FT                   /note="N-acetylalanine"
FT                   /evidence="ECO:0000250|UniProtKB:P05771"
FT   MOD_RES         11
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         16
FT                   /note="Phosphoserine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:8327493"
FT   MOD_RES         17
FT                   /note="Phosphothreonine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:8327493"
FT   MOD_RES         206
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P05771"
FT   MOD_RES         250
FT                   /note="Phosphothreonine; by autocatalysis"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         314
FT                   /note="Phosphothreonine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:8327493"
FT   MOD_RES         324
FT                   /note="Phosphothreonine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:8327493"
FT   MOD_RES         500
FT                   /note="Phosphothreonine; by PDPK1"
FT                   /evidence="ECO:0000305|PubMed:21215369,
FT                   ECO:0000305|PubMed:7961692, ECO:0000305|PubMed:8749392"
FT   MOD_RES         504
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:P05771"
FT   MOD_RES         635
FT                   /note="Phosphothreonine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:8327493"
FT   MOD_RES         642
FT                   /note="Phosphothreonine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:21215369,
FT                   ECO:0000269|PubMed:8327493, ECO:0000269|PubMed:8749392,
FT                   ECO:0007744|PubMed:22673903"
FT   MOD_RES         661
FT                   /note="Phosphoserine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:21215369,
FT                   ECO:0000269|PubMed:8749392"
FT   MOD_RES         662
FT                   /note="Phosphotyrosine; by SYK"
FT                   /evidence="ECO:0000250|UniProtKB:P68404"
FT   VAR_SEQ         622..671
FT                   /note="RDKRDTSNFDKEFTRQPVELTPTDKLFIMNLDQNEFAGFSYTNPEFVINV
FT                   -> CGRNAENFDRFFTRHPPVLTPPDQEVIRNIDQSEFEGFSFVNSEFLKPEVKS (in
FT                   isoform Beta-II)"
FT                   /evidence="ECO:0000303|PubMed:2428667,
FT                   ECO:0000303|PubMed:3755379"
FT                   /id="VSP_004739"
FT   MUTAGEN         16..17
FT                   /note="ST->AA: No effect."
FT                   /evidence="ECO:0000269|PubMed:8327493"
FT   MUTAGEN         314
FT                   /note="T->A: No effect; when associated with A-323."
FT                   /evidence="ECO:0000269|PubMed:8327493"
FT   MUTAGEN         324
FT                   /note="T->A: No effect; when associated with A-313."
FT                   /evidence="ECO:0000269|PubMed:8327493"
FT   MUTAGEN         500
FT                   /note="T->E: 50% increase of enzymatic activity."
FT                   /evidence="ECO:0000269|PubMed:7961692"
FT   MUTAGEN         500
FT                   /note="T->S: 50% decrease of enzymatic activity."
FT                   /evidence="ECO:0000269|PubMed:7961692"
FT   MUTAGEN         500
FT                   /note="T->V,D: Loss of enzymatic activity."
FT                   /evidence="ECO:0000269|PubMed:7961692"
FT   MUTAGEN         635
FT                   /note="T->A: Loss of enzymatic activity; when associated
FT                   with T-643 change in subcellular location, loss of PMA-
FT                   induced down-regulation and loss of enzymatic activity."
FT                   /evidence="ECO:0000269|PubMed:8034726,
FT                   ECO:0000269|PubMed:8327493"
FT   MUTAGEN         642
FT                   /note="T->A: Loss of enzymatic activity; when associated
FT                   with T-636 change in subcellular location, loss of PMA-
FT                   induced down-regulation and loss of enzymatic activity."
FT                   /evidence="ECO:0000269|PubMed:8034726,
FT                   ECO:0000269|PubMed:8327493"
FT   CONFLICT        25
FT                   /note="A -> P (in Ref. 3; AAA41868)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        126
FT                   /note="I -> V (in Ref. 1; AAA41875)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        138
FT                   /note="N -> S (in Ref. 1; AAA41875)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        141
FT                   /note="K -> R (in Ref. 1; AAA41875)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        149
FT                   /note="S -> G (in Ref. 1; AAA41875)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        164
FT                   /note="I -> V (in Ref. 1; AAA41875)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        170..171
FT                   /note="RE -> GG (in Ref. 1; AAA41875)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        174
FT                   /note="I -> V (in Ref. 1; AAA41875)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        294
FT                   /note="G -> E (in Ref. 3; AAA41868)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        419
FT                   /note="V -> M (in Ref. 2; CAA28035/CAA28036)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        628
FT                   /note="Missing (in Ref. 1; AAA41865)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        640
FT                   /note="Missing (in Ref. 1; AAA41865)"
FT                   /evidence="ECO:0000305"
FT   STRAND          161..182
FT                   /evidence="ECO:0007829|PDB:1A25"
FT   STRAND          194..202
FT                   /evidence="ECO:0007829|PDB:1A25"
FT   STRAND          222..230
FT                   /evidence="ECO:0007829|PDB:1A25"
FT   HELIX           234..237
FT                   /evidence="ECO:0007829|PDB:1A25"
FT   STRAND          239..246
FT                   /evidence="ECO:0007829|PDB:1A25"
FT   STRAND          249..251
FT                   /evidence="ECO:0007829|PDB:1A25"
FT   STRAND          254..262
FT                   /evidence="ECO:0007829|PDB:1A25"
FT   HELIX           263..266
FT                   /evidence="ECO:0007829|PDB:1A25"
FT   STRAND          271..276
FT                   /evidence="ECO:0007829|PDB:1A25"
FT   HELIX           280..283
FT                   /evidence="ECO:0007829|PDB:1A25"
FT   MOD_RES         P68403-2:641
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         P68403-2:654
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         P68403-2:660
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         P68403-2:664
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
SQ   SEQUENCE   671 AA;  76751 MW;  A1935030F758513C CRC64;
     MADPAAGPPP SEGEESTVRF ARKGALRQKN VHEVKNHKFT ARFFKQPTFC SHCTDFIWGF
     GKQGFQCQVC CFVVHKRCHE FVTFSCPGAD KGPASDDPRS KHKFKIHTYS SPTFCDHCGS
     LLYGLIHQGM KCDTCMMNVH KRCVMNVPSL CGTDHTERRG RIYIQAHIDR EVLIVVVRDA
     KNLVPMDPNG LSDPYVKLKL IPDPKSESKQ KTKTIKCSLN PEWNETFRFQ LKESDKDRRL
     SVEIWDWDLT SRNDFMGSLS FGISELQKAG VDGWFKLLSQ EEGEYFNVPV PPEGSEGNEE
     LRQKFERAKI GQGTKAPEEK TANTISKFDN NGNRDRMKLT DFNFLMVLGK GSFGKVMLSE
     RKGTDELYAV KILKKDVVIQ DDDVECTMVE KRVLALPGKP PFLTQLHSCF QTMDRLYFVM
     EYVNGGDLMY HIQQVGRFKE PHAVFYAAEI AIGLFFLQSK GIIYRDLKLD NVMLDSEGHI
     KIADFGMCKE NIWDGVTTKT FCGTPDYIAP EIIAYQPYGK SVDWWAFGVL LYEMLAGQAP
     FEGEDEDELF QSIMEHNVAY PKSMSKEAVA ICKGLMTKHP GKRLGCGPEG ERDIKEHAFF
     RYIDWEKLER KEIQPPYKPK ARDKRDTSNF DKEFTRQPVE LTPTDKLFIM NLDQNEFAGF
     SYTNPEFVIN V
//
